|
| 36331056 | Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans. | Alzheimers Dement | 2023 |
| 37461624 | Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies <i>LRRC4C, LHX5-AS1</i> and nominates ancestry-specific loci <i>PTPRK</i> , <i>GRB14</i> , and <i>KIAA0825</i> as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium. | medRxiv | 2023 |
| 36648159 | Initial non-amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias. | Alzheimers Dement | 2023 |
| 36847000 | Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care. | J Alzheimers Dis | 2023 |
| 36873923 | Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel. | Alzheimers Dement (N Y) | 2023 |
| 36512061 | LATE-NC staging in routine neuropathologic diagnosis: an update. | Acta Neuropathol | 2023 |
| 36927447 | Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease. | Alzheimers Res Ther | 2023 |
| 36239924 | Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design. | Alzheimers Dement | 2023 |
| 34310044 | Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial. | Alzheimers Dement | 2022 |
| 35379761 | Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies. | Neurology | 2022 |
| 35523454 | Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease. | J Immunol | 2022 |
| 36450252 | Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease. | Cell Rep | 2022 |
| 36254161 | The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease. | Alzheimers Dement (N Y) | 2022 |
| 35012639 | Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease. | Alzheimers Res Ther | 2022 |
| 35238936 | Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology. | JAMA Netw Open | 2022 |
| 35173668 | Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. | Front Neurol | 2022 |
| 33009039 | Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts. | Alzheimer Dis Assoc Disord | 2021 |
| 33627474 | Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. | Genome Res | 2021 |
| 33716716 | <i>TNFRSF1B</i> Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease. | Front Aging Neurosci | 2021 |
| 33791705 | Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. | bioRxiv | 2021 |
| 33485373 | Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer's and Lewy body neuropathology. | Alzheimers Res Ther | 2021 |
| 33589841 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. | Nat Genet | 2021 |
| 33814445 | Unique Sleep and Circadian Rhythm Dysfunction Neuroinflammatory and Immune Profiles in Alzheimer's Disease with Mild Cognitive Impairment. | J Alzheimers Dis | 2021 |
| 33614888 | Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. | Alzheimers Dement (N Y) | 2021 |
| 34541289 | Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. | Alzheimers Dement (Amst) | 2021 |
| 34108016 | Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. | Alzheimers Res Ther | 2021 |
| 34276339 | Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. | Front Aging Neurosci | 2021 |
| 33967045 | Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOEÉ¿4 Status. | J Alzheimers Dis | 2021 |
| 34238345 | Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. | Alzheimers Res Ther | 2021 |
| 33977271 | High resolution structural and functional MRI of the hippocampus in young adults with Down syndrome. | Brain Commun | 2021 |
| 33976533 | The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. | Drug Des Devel Ther | 2021 |
| 33445953 | Amyloid Precursor Protein Variant, E665D, Associated With Unique Clinical and Biomarker Phenotype. | Am J Alzheimers Dis Other Demen | 2021 |
| 33070299 | High-resolution functional connectivity of the default mode network in young adults with down syndrome. | Brain Imaging Behav | 2021 |
| 33441136 | AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery. | Alzheimers Res Ther | 2021 |
| 32285645 | Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. | Ann Clin Transl Neurol | 2020 |
| 31871218 | Longitudinal change in regional brain volumes with exposure to repetitive head impacts. | Neurology | 2020 |
| 31959733 | An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report. | J Immunol | 2020 |
| 31959685 | Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. | Neurology | 2020 |
| 33121510 | Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. | Alzheimers Res Ther | 2020 |
| 32634865 | Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease. | Ann Clin Transl Neurol | 2020 |
| 32656864 | Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. | Med Res Rev | 2020 |
| 32881874 | Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases. | PLoS One | 2020 |
| 32868302 | Emerging blood-based biomarkers for Alzheimer disease. | Cleve Clin J Med | 2020 |
| 32241955 | Research criteria for the diagnosis of prodromal dementia with Lewy bodies. | Neurology | 2020 |
| 32558217 | Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study. | Alzheimers Dement | 2020 |
| 30745444 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. | Neurology | 2019 |
| 31683482 | Clinical and Imaging Characteristics Associated with Color Vision Impairment in Lewy Body Disease. | J Alzheimers Dis | 2019 |
| 32368733 | Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. | Clin Park Relat Disord | 2019 |
| 31614096 | Clinical drug development for dementia with Lewy bodies: past and present. | Expert Opin Investig Drugs | 2019 |
| 31353852 | Key inflammatory pathway activations in the MCI stage of Alzheimer's disease. | Ann Clin Transl Neurol | 2019 |